COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,704 Articles (22,913 medRxiv, 8,791 bioRxiv)

Most recent first Previous |  Page 378: Articles 3771-3780  | Next

Influence of age, sex, body habitus, vaccine type and anti-S serostatus on cellular and humoral responses to SARS-CoV-2 vaccination
Chambers, E. S., Cai, W., Cousens, A. K., Vivaldi, G., Jolliffe, D. A., Perdek, N., Li, W., Faustini, S. E., Gibbons, J. M., Pade, C., Richter, A. G., Martineau, A. R.
10.1101/2023.09.29.23296222 — Posted: 2023-09-29
Prevalence of COVID-19 and long COVID - Results from the 2022 Behavioral Risk Factor Surveillance System, 50 states.
Adams, M. L., Grandpre, J.
10.1101/2023.09.29.23296352 — Posted: 2023-09-29
Endemic means change as SARS-CoV-2 evolves
Otto, S., MacPherson, A., Colijn, C.
10.1101/2023.09.28.23296264 — Posted: 2023-09-29
Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion
Septisetyani, E. P. P., Lestari, D., Paramitasari, K. A., Prasetyaningrum, P. W., Kastian, R. F., Santoso, A., Eriani, K.
10.1101/2023.09.28.560070 — Posted: 2023-09-29
POP-UP TCR: Prediction of Previously Unseen Paired TCR-pMHC
Tickotsky, N.
10.1101/2023.09.28.560071 — Posted: 2023-09-29
Protective non-neutralizing mAbs targets conserved opsonic epitopes on SARS-CoV-2 variants
Izadi, A., Godzwon, M., Ohlin, M., Nordenfelt, P.
10.1101/2023.09.29.560084 — Posted: 2023-09-29
Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance
Flynn, J. M., Duggan, S. N., Shaqra, A. M., Dovala, D., Schiffer, C. A., Bolon, D.
10.1101/2023.09.28.560010 — Posted: 2023-09-29
The Role of ATP Hydrolysis and Product Release in the Translocation Mechanism of SARS-CoV-2 NSP13
Lawal, M. M., Roy, P., McCullagh, M.
10.1101/2023.09.28.560057 — Posted: 2023-09-29
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Ma, Y., Ma, X., Vulupala, V. R., Atla, S., Blankenship, L., Coleman, D., Neuman, B. W., Liu, W., Xu, S.
10.1101/2023.09.29.560163 — Posted: 2023-09-29
Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases.
Agamah, F. E., Ederveen, T. H. A., Skelton, M., Martin, D. P., Chimusa, E. R., 't Hoen, P. A. C.
10.1101/2023.09.29.560110 — Posted: 2023-09-29

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).